Last reviewed · How we verify
Intravenous DNase I
Intravenous DNase I is a Small molecule drug developed by McMaster University. It is currently in Phase 1 development.
At a glance
| Generic name | Intravenous DNase I |
|---|---|
| Sponsor | McMaster University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intravenous DNase I for the Treatment of Sepsis (IDEALSepsisI) (PHASE1)
- Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase) (PHASE2)
- Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous DNase I CI brief — competitive landscape report
- Intravenous DNase I updates RSS · CI watch RSS
- McMaster University portfolio CI
Frequently asked questions about Intravenous DNase I
What is Intravenous DNase I?
Intravenous DNase I is a Small molecule drug developed by McMaster University.
Who makes Intravenous DNase I?
Intravenous DNase I is developed by McMaster University (see full McMaster University pipeline at /company/mcmaster-university).
What development phase is Intravenous DNase I in?
Intravenous DNase I is in Phase 1.
Related
- Manufacturer: McMaster University — full pipeline
- Compare: Intravenous DNase I vs similar drugs
- Pricing: Intravenous DNase I cost, discount & access